Relmada Therapeutics, a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced that James Dolan, formerly Senior Vice President of Licensing and Business Development at Purdue Pharma L.P., has joined Relmada as an advisory partner.
Mr. Dolan brings to Relmada more than 36 years of experience in the life sciences industry, including expertise in business development and licensing of pain management therapies like those under development at Relmada. On December 10, 2015, Relmada announced positive topline results of a proof-of-concept pharmacokinetic study for BuTab. These results demonstrated for the first time that buprenorphine can be delivered at therapeutic levels through the gastrointestinal route. Mr. Dolan's appointment as an advisor to the Company reflects the significant progress Relmada is making – and is expected to continue making – to develop BuTab and other products in its pipeline.
"We are delighted to welcome Jim as an advisor to Relmada," said Sergio Traversa, Chief Executive Officer of Relmada Therapeutics. "We expect his industry insights, contacts and business development expertise to contribute to the progress we are making to advance Relmada's product portfolio, creating benefits for patients and driving value for Relmada stockholders. As we have said, this is a time of opportunity for Relmada. We have a strong team, robust portfolio and clear development plan that includes many value-creation opportunities over the next 12 to 24 months. We are looking ahead with great enthusiasm and confidence in our company."
"Relmada's positive success to date, including the recently announced BuTab results, reflects the strength of the Company's Board and management team," Mr. Dolan said. "I am excited to have the opportunity to advise this team as it further advances the clinical, regulatory and commercial development of Relmada's product pipeline. I share Sergio's confidence in Relmada and where the Company is headed."
About James Dolan
Mr. Dolan is an experienced biopharmaceutical executive with more than 36 years of pharma/biotech industry experience, including in the areas of global finance, strategic planning, pharmaceutical marketing and business development.
Mr. Dolan presently serves as a consultant to universities and biotech boards and investors regarding the development of early-stage technologies and transactional strategies.
He previously served as Senior Vice President of Licensing and Business Development and as a member of the Executive Committee of Purdue Pharma L.P. During his almost 20-year tenure at Purdue, a leading company in the pain management therapeutics area, he was responsible for all external transactions from early-stage discovery alliances to licensing, asset purchases, product licenses, strategic alliances, equity investments and company acquisitions. In support of Purdue's equity investments in Infinity Pharmaceuticals and Kolltan Pharmaceuticals, Mr. Dolan served as board observer at both companies.
Prior to Purdue, Mr. Dolan spent 15 years at Pfizer in the International Pharmaceuticals Group, where he held operational management positions at subsidiaries in Brazil and Morocco, following international finance and strategic planning roles in New York.
Mr. Dolan was a two-term president of the New York Pharma Forum and he has been actively involved with BIO and the Licensing Executive Society.
Mr. Dolan holds a BA degree from Holy Cross and an MBA from the University of Connecticut.